Neuphoria Therapeutics Inc.
NEUP · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $1 | $5 | $9 |
| - Cash | $14 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$14 | $1 | $5 | $9 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | -$0 | -$0 | $0 |
| % Margin | 95.8% | – | – | 0% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1.1% | – | – | -10,085.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2.4% | – | – | -8,253.6% |
| EPS Diluted | -0.23 | -0.1 | -0.17 | -0.13 |
| % Growth | -130% | 41.2% | -30.8% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |